Lacosamide Fresenius Kab

Lacosamide, the active ingredient in Lacosamide Fresenius Kab, is a sodium channel blocker presented as an injectable solution for intravenous use. It is used as adjunctive therapy to control focal seizures in patients with epilepsy.

GNH USA supplies Lacosamide Fresenius Kab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an antiepileptic drug that acts on focal seizure pathways.

Focal seizures: reduces seizure frequency as add‑on therapy in adults. Partial‑onset seizures: improves seizure control when combined with other antiepileptics. Pediatric focal seizures (≥4 years): provides additional seizure reduction as adjunctive treatment.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Fatigue: feeling of tiredness or reduced energy. - Diplopia: temporary double vision. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or atrioventricular block. - Suicidal ideation: emergence of depressive thoughts or behaviors. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Elevated liver enzymes: signs of hepatic injury.

Before initiating therapy, consider the following precautions.

Renal impairment: monitor renal function and adjust dosing if needed. Cardiac conduction disorders: obtain baseline ECG and watch for PR‑interval changes. History of psychiatric disorders: observe for mood changes or suicidal thoughts. Pregnancy: use only when benefit outweighs potential risk, as category is unknown. Concomitant CYP3A4 inhibitors: assess for possible increased lacosamide exposure. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lacosamide may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly reduce lacosamide plasma levels. - Concomitant agents that prolong PR interval (e.g., diltiazem, verapamil): increase risk of cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, carbamazepine): may alter lacosamide concentrations. - Renal excretion modifiers (e.g., probenecid): can raise lacosamide levels. - Alcohol: may enhance central nervous system depression.